IGF-1 and Peptides: How Growth Hormone Secretagogues Increase IGF-1 Levels

IGF-1 and Peptides: A Comprehensive Research Guide to Growth Hormone Secretagogues and IGF-1 Modulation

Insulin-like Growth Factor 1 (IGF-1) stands as one of the most powerful anabolic hormones in the human body, serving as the primary mediator of growth hormone’s (GH) downstream effects on virtually every tissue system. From skeletal muscle hypertrophy and bone mineral density to cognitive function and tissue repair, IGF-1 orchestrates a vast array of physiological processes that collectively determine an organism’s regenerative capacity, metabolic efficiency, and biological age. As research into IGF-1 peptides continues to expand, scientists have identified multiple growth hormone secretagogue (GHS) compounds capable of meaningfully elevating IGF-1 levels through stimulation of the hypothalamic-pituitary-somatotroph axis.

This guide provides a thorough examination of IGF-1 biology, the molecular signaling cascades it activates, the mechanisms by which peptide-based GH secretagogues augment IGF-1 production, and the practical considerations for researchers designing protocols around IGF-1 optimization. Whether you are investigating peptide research for the first time or designing advanced multi-compound studies, understanding the IGF-1 axis is foundational to modern peptide science.

Chapter 1: IGF-1 Biology — Production, Structure, and Regulation

1.1 Hepatic Production and the GH-IGF-1 Axis

IGF-1 is a 70-amino acid polypeptide hormone with significant structural homology to proinsulin. Approximately 75–80% of circulating IGF-1 is synthesized in the liver in direct response to growth hormone stimulation, a relationship first characterized by Salmon and Daughaday in 1957 and later refined through decades of molecular endocrinology research (PMID: 13385769). The remaining 20–25% is produced locally in peripheral tissues including muscle, bone, brain, kidney, and cartilage, where it acts in autocrine and paracrine fashions.

The GH-IGF-1 axis operates through a well-characterized endocrine cascade. Growth hormone-releasing hormone (GHRH) from the arcuate nucleus of the hypothalamus stimulates somatotroph cells in the anterior pituitary to secrete GH in pulsatile bursts. GH then travels to hepatocytes, where it binds to the growth hormone receptor (GHR), activating the JAK2-STAT5b signaling pathway. STAT5b directly transactivates the IGF1 gene promoter, initiating transcription of IGF-1 mRNA and subsequent protein synthesis and secretion into the circulation (PMID: 16322161).

This system features a critical negative feedback loop: circulating IGF-1 suppresses GH secretion at both the hypothalamic level (stimulating somatostatin release) and the pituitary level (directly inhibiting somatotroph GH release). This feedback mechanism is why exogenous IGF-1 administration suppresses endogenous GH production, whereas IGF-1 peptides that work through GH secretagogue pathways maintain physiological feedback regulation — a distinction of enormous importance for research protocol design. For a foundational understanding of GH-releasing peptides, see our growth hormone secretagogues complete guide.

1.2 IGF-1 Binding Proteins: IGFBP-1 Through IGFBP-6

Unlike most peptide hormones that circulate freely, approximately 99% of circulating IGF-1 is bound to one of six high-affinity IGF binding proteins (IGFBPs). This binding protein system provides a reservoir mechanism that extends IGF-1’s half-life from approximately 10–12 minutes (free) to 12–15 hours (bound), regulates tissue-specific bioavailability, and modulates IGF-1 receptor interactions (PMID: 11701431).

The six binding proteins have distinct regulatory roles:

• IGFBP-3 — The most abundant binding protein, carrying approximately 75–80% of circulating IGF-1 in a ternary complex with acid-labile subunit (ALS). IGFBP-3 is itself GH-dependent, rising and falling with IGF-1. This ternary complex (IGF-1 + IGFBP-3 + ALS) represents the primary circulating reservoir and has a half-life of approximately 12–15 hours.
• IGFBP-1 — Acutely regulated by insulin (inversely) and serves as a rapid modulator of free IGF-1 bioavailability. Fasting elevates IGFBP-1, reducing free IGF-1; feeding suppresses IGFBP-1, increasing free IGF-1. This is why nutritional status dramatically affects IGF-1 bioactivity.
• IGFBP-2 — The second most abundant circulating IGFBP. Elevated in catabolic states and GH deficiency. IGFBP-2 generally inhibits IGF-1 action and is associated with insulin sensitivity.
• IGFBP-4 — Primarily inhibitory; cleaved by pregnancy-associated plasma protein-A (PAPP-A) to release free IGF-1 locally, particularly important in bone and ovarian follicle biology.
• IGFBP-5 — The most conserved IGFBP across species. Plays critical roles in bone formation and can both potentiate and inhibit IGF-1 action depending on whether it is matrix-bound or soluble (PMID: 10404020).
• IGFBP-6 — Preferentially binds IGF-II over IGF-1 (20–100 fold higher affinity) and is considered primarily a regulator of IGF-II-dependent processes including certain cancer pathways.

1.3 Free IGF-1 vs. Total IGF-1

Standard clinical laboratory assays measure total IGF-1 (bound + free), but only free IGF-1 (approximately 1% of total) is immediately bioavailable for receptor binding and signaling. Research has increasingly emphasized the importance of free IGF-1 measurements, as the ratio of free to total IGF-1 can shift significantly based on nutritional status, insulin levels, IGFBP protease activity, and hepatic function (PMID: 11502783).

For researchers using IGF-1 peptides and GH secretagogues, total IGF-1 remains the standard monitoring biomarker due to assay availability and reproducibility. However, understanding that total IGF-1 only partially reflects bioactive IGF-1 concentrations is critical for interpreting research data. Our peptide blood work guide provides detailed protocols for monitoring IGF-1 and related biomarkers during peptide research.

1.4 Tissue-Specific IGF-1 Effects

While circulating (endocrine) IGF-1 from the liver was long considered the primary driver of IGF-1’s systemic effects, landmark studies using liver-specific IGF-1 knockout mice demonstrated that locally produced (autocrine/paracrine) IGF-1 accounts for a substantial portion of IGF-1’s tissue-specific actions. These liver IGF-1-deficient (LID) mice maintained near-normal body growth despite 75% reductions in circulating IGF-1, indicating that local IGF-1 production in muscle, bone, and other tissues significantly contributes to growth and maintenance (PMID: 10202149).

This finding has important implications for GH secretagogue research: by stimulating pulsatile GH release, these peptides increase both hepatic (circulating) and local (tissue) IGF-1 production simultaneously, potentially providing more comprehensive IGF-1-mediated effects than exogenous IGF-1 administration alone.

Chapter 2: IGF-1 Signaling Pathways — PI3K/Akt, MAPK/ERK, and mTOR

2.1 The IGF-1 Receptor (IGF-1R)

IGF-1 exerts its cellular effects primarily through the type 1 IGF receptor (IGF-1R), a transmembrane receptor tyrosine kinase with significant structural homology to the insulin receptor. Upon IGF-1 binding, IGF-1R undergoes autophosphorylation on specific tyrosine residues in its intracellular kinase domain, creating docking sites for downstream signaling molecules including insulin receptor substrates (IRS-1 through IRS-4) and Shc adaptor proteins (PMID: 17482555).

2.2 PI3K/Akt Pathway

The PI3K/Akt pathway represents IGF-1’s primary survival and anabolic signaling cascade. Upon IGF-1R activation, IRS-1 is phosphorylated and recruits phosphoinositide 3-kinase (PI3K) to the membrane. PI3K generates phosphatidylinositol-3,4,5-trisphosphate (PIP3), which activates phosphoinositide-dependent kinase 1 (PDK1) and subsequently Akt (also known as protein kinase B).

Activated Akt phosphorylates numerous downstream targets with diverse biological consequences:

• mTORC1 activation — Akt phosphorylates and inhibits tuberous sclerosis complex 2 (TSC2), releasing mTORC1 from inhibition. mTORC1 then phosphorylates p70S6K and 4E-BP1, directly stimulating cap-dependent mRNA translation and protein synthesis — the molecular basis of IGF-1’s anabolic effects.
• GSK-3? inhibition — Akt phosphorylates and inactivates glycogen synthase kinase 3?, promoting glycogen synthesis and inhibiting pro-apoptotic pathways.
• FOXO transcription factor suppression — Akt phosphorylates FOXO1, FOXO3, and FOXO4, causing their nuclear exclusion and ubiquitin-mediated degradation. Since FOXO factors drive expression of atrogenes (MuRF1, MAFbx/atrogin-1), their suppression by IGF-1/Akt signaling provides powerful anti-catabolic protection for skeletal muscle (PMID: 15337765).
• BAD phosphorylation — Akt phosphorylates the pro-apoptotic protein BAD, preventing it from sequestering anti-apoptotic Bcl-2 and Bcl-XL, thereby promoting cell survival.

2.3 MAPK/ERK Pathway

The second major signaling arm of IGF-1R involves the Ras-Raf-MEK-ERK (MAPK) cascade. IGF-1R activation leads to Shc phosphorylation, recruitment of Grb2-SOS complex, and activation of Ras GTPase. Activated Ras initiates the kinase cascade through Raf ? MEK1/2 ? ERK1/2 (PMID: 11972060).

The MAPK/ERK pathway primarily mediates IGF-1’s mitogenic (cell proliferation) and differentiative effects, including satellite cell activation in skeletal muscle, osteoblast proliferation in bone, and neuronal differentiation in the central nervous system. While the PI3K/Akt pathway primarily drives protein synthesis and cell survival, the MAPK/ERK pathway complements these effects by promoting cell cycle progression and tissue-specific differentiation programs.

2.4 mTOR Activation and Protein Synthesis

The mechanistic target of rapamycin (mTOR) deserves special emphasis as the convergence point of IGF-1’s anabolic signaling. mTOR exists in two distinct complexes — mTORC1 and mTORC2 — each with different regulatory roles. IGF-1 activates mTORC1 through the PI3K/Akt/TSC2 pathway described above, while mTORC2 is activated through a less well-characterized mechanism involving ribosome association (PMID: 22770212).

mTORC1 activation by IGF-1 stimulates muscle protein synthesis (MPS) through two primary effectors: p70S6 kinase (S6K1), which phosphorylates ribosomal protein S6 to enhance translation of mRNAs encoding ribosomal proteins and elongation factors; and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), whose phosphorylation releases eIF4E to form the eIF4F cap-binding complex necessary for cap-dependent translation initiation. This dual mechanism accounts for IGF-1’s powerful stimulation of muscle protein synthesis, which can increase MPS rates by 30–50% above baseline in research models. Researchers investigating anabolic optimization should also review our peptide stacking guide for complementary approaches.

Chapter 3: Age-Related IGF-1 Decline — The Somatopause

3.1 Decade-by-Decade IGF-1 Levels

One of the most consistent findings in endocrinology is the progressive, age-related decline in circulating IGF-1 levels, a phenomenon termed the “somatopause” by analogy with menopause and andropause. After peaking during puberty (typically 300–500 ng/mL), IGF-1 levels decline approximately 14% per decade throughout adult life (PMID: 9094086).

Typical age-adjusted IGF-1 reference ranges based on large population studies include:

This decline parallels the well-documented age-related reduction in GH pulse amplitude (with relatively preserved pulse frequency), decreased GH receptor expression in the liver, and increased somatostatin tone. The somatopause contributes significantly to sarcopenia, osteopenia, increased adiposity, thinning skin, cognitive decline, and impaired wound healing that characterize biological aging. Our anti-aging peptides longevity guide explores how peptide interventions may address these age-related changes.

3.2 Drivers of Age-Related Decline

The somatopause is not simply a consequence of pituitary exhaustion. Multiple mechanisms contribute to declining IGF-1 with age:

• Increased somatostatin tone — The hypothalamus produces progressively more somatostatin with age, which suppresses GH release. This is the primary target of GH secretagogues that override somatostatin-mediated inhibition.
• Decreased GHRH production — Hypothalamic GHRH neurons show age-related atrophy, reducing the stimulatory drive on pituitary somatotrophs.
• Reduced pituitary GH stores — While the pituitary retains the capacity to release GH at any age (demonstrated by pharmacological provocation tests), baseline GH stores decrease modestly with aging.
• Adiposity — Visceral adiposity is strongly inversely correlated with GH and IGF-1 levels. Each unit increase in BMI is associated with approximately 6% decrease in GH secretion, creating a self-reinforcing cycle of declining GH/IGF-1 and increasing fat mass (PMID: 7615555).
• Sleep disruption — GH is predominantly secreted during slow-wave (N3) sleep. Age-related decline in slow-wave sleep directly reduces nocturnal GH pulses and consequently hepatic IGF-1 production. For more on this relationship, see our guide on peptides for sleep and GH secretagogues.
• Hepatic GH resistance — Liver GH receptor expression and signaling efficiency decline with age, meaning the same amount of GH produces less IGF-1 in older organisms.

Chapter 4: How Growth Hormone Secretagogues Increase IGF-1

4.1 Mechanism of GH Secretagogue-Mediated IGF-1 Elevation

Growth hormone secretagogues (GHS) increase IGF-1 indirectly by stimulating endogenous pulsatile GH release from the anterior pituitary. Unlike exogenous GH administration, which creates a single supraphysiological peak followed by a prolonged trough, GHS compounds restore or amplify the natural pulsatile pattern of GH release. This pulsatile pattern is critical because hepatocytes respond to GH pulse amplitude (not trough levels) for IGF-1 gene transcription — a distinction that significantly impacts the quality and sustainability of IGF-1 elevation (PMID: 11836277).

There are two primary classes of GH secretagogues relevant to IGF-1 peptides research:

• GHRH analogs — Compounds like CJC-1295 (modified GHRH) that directly stimulate pituitary somatotrophs via the GHRH receptor, increasing GH pulse amplitude.
• Ghrelin mimetics (GHRPs/GHS-R agonists) — Compounds like Ipamorelin that act through the growth hormone secretagogue receptor (GHS-R1a, also known as the ghrelin receptor), amplifying GH release through a pathway distinct from GHRH.

The synergy between these two classes is well-documented: GHRH analogs increase GH pulse amplitude while ghrelin mimetics increase both pulse amplitude and frequency, and their combined administration produces GH release 2–3 times greater than either agent alone. This synergistic GH elevation translates to proportionally greater IGF-1 increases, forming the basis of the CJC-1295 + Ipamorelin combination protocol widely used in research. For beginners approaching this topic, our peptide research for beginners guide provides essential context.

4.2 CJC-1295 and IGF-1 Elevation

CJC-1295 is a synthetic analog of GHRH (growth hormone-releasing hormone) consisting of the first 29 amino acids of GHRH with four amino acid substitutions (Ala2, Gln8, Ala15, Leu27) that confer resistance to dipeptidyl peptidase IV (DPP-IV) cleavage, dramatically extending its half-life. Two forms exist: CJC-1295 with Drug Affinity Complex (DAC), which binds albumin and has a half-life of approximately 6–8 days, and CJC-1295 without DAC (also called Modified GRF 1-29), which has a half-life of approximately 30 minutes.

Clinical data on CJC-1295 with DAC demonstrated sustained IGF-1 elevation. In a pivotal single-dose escalation study, subcutaneous CJC-1295 DAC at doses of 30, 60, and 125 µg/kg produced dose-dependent IGF-1 increases that persisted for 6–14 days after a single injection. At the 60 µg/kg dose, mean IGF-1 levels increased by 1.5–2 fold above baseline, peaking at day 2–3 and remaining elevated above baseline for 8–11 days (PMID: 16352683).

After multiple weekly doses, steady-state IGF-1 elevations of 1.6–2.0 fold above baseline were observed, with the magnitude of elevation being dose-dependent. Importantly, the pulsatile nature of GH release was preserved — CJC-1295 amplified existing GH pulses rather than creating a continuous non-physiological GH elevation, resulting in more physiological IGF-1 kinetics.

CJC-1295 without DAC (Modified GRF 1-29), due to its shorter half-life, produces acute GH pulses when administered 2–3 times daily. While individual GH pulses are larger than with DAC, the shorter duration means IGF-1 elevation is more moderate on a 24-hour average basis. Research protocols typically employ 100 µg doses 2–3 times daily (often before bed and upon waking), producing IGF-1 elevations of approximately 1.3–1.6 fold above baseline at steady state.

4.3 Ipamorelin and IGF-1 Elevation

Ipamorelin is a pentapeptide GH secretagogue (Aib-His-D-2Nal-D-Phe-Lys-NH2) that selectively stimulates GH release through the GHS-R1a receptor without significant effects on cortisol, prolactin, or ACTH — a selectivity profile unique among GH secretagogues. This selectivity makes Ipamorelin the cleanest GH-releasing peptide available for research (PMID: 9849822).

In clinical studies, Ipamorelin administered intravenously at 1 µg/kg produced GH peak concentrations of approximately 35 µg/L, comparable to GHRP-6 but without the hunger-stimulating, cortisol-raising, and prolactin-elevating side effects. Subcutaneous dosing in research protocols (typically 200–300 µg per administration) produces GH peaks within 20–40 minutes, with GH levels returning to baseline within 2–3 hours.

When administered chronically (2–3 times daily for 4+ weeks), Ipamorelin alone produces modest but consistent IGF-1 elevation of approximately 1.2–1.4 fold above baseline. However, its primary value in IGF-1 research lies in its synergistic combination with CJC-1295, where the dual-pathway stimulation produces significantly greater IGF-1 responses than either peptide alone.

4.4 Tesamorelin Clinical Trials and IGF-1 Data

Tesamorelin (formerly TH9507) is a synthetic GHRH analog consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus, providing DPP-IV resistance. It is the only FDA-approved GHRH analog (marketed as Egrifta® for HIV-associated lipodystrophy), providing the most robust clinical trial data for GH secretagogue-mediated IGF-1 elevation.

In the pivotal Phase III trials of Tesamorelin (2 mg subcutaneous daily for 26 weeks), IGF-1 outcomes were extensively documented:

• Mean IGF-1 increased from baseline of approximately 150 ng/mL to approximately 250 ng/mL — a 1.67-fold increase (PMID: 17956947).
• The IGF-1 standard deviation score (SDS) increased from approximately -1.0 to approximately +0.5, indicating normalization of age-adjusted IGF-1 levels.
• IGF-1 elevation occurred rapidly, with significant increases detectable within 2 weeks and plateau levels reached by week 8–12.
• Upon discontinuation, IGF-1 returned to baseline within 4–6 weeks, confirming reversibility and the absence of permanent axis changes.
• IGFBP-3 levels increased proportionally with IGF-1, maintaining a normal IGF-1/IGFBP-3 ratio.

A 52-week extension study confirmed sustained IGF-1 elevation without tachyphylaxis (tolerance), with year-over-year IGF-1 levels remaining stable at approximately 1.5–1.7 fold above baseline (PMID: 24037882). This long-term data is particularly valuable for research protocol design, as it demonstrates that GHRH-based GH secretagogues can maintain elevated IGF-1 without dose escalation or receptor desensitization.

4.5 Dose-Response Relationships

The relationship between GH secretagogue dose and IGF-1 elevation follows a sigmoidal curve with a clear ceiling effect, reflecting the finite GH storage capacity of pituitary somatotrophs. Key dose-response principles for research include:

Beyond the plateau dose, additional GH secretagogue administration produces minimal incremental IGF-1 elevation but may increase side effects (water retention, paresthesias, joint stiffness). This ceiling effect reflects somatotroph GH store depletion and should guide maximum dosing in research protocols. For detailed dosing calculations, use our peptide dosage calculator.

Chapter 5: Optimal IGF-1 Ranges — The U-Shaped Mortality Curve

5.1 Too Low: Catabolic, Aging, and Degenerative States

IGF-1 deficiency, whether from GH deficiency, malnutrition, liver disease, or severe aging, produces a constellation of catabolic and degenerative changes:

• Sarcopenia — Muscle protein synthesis rates decline 30–50%, with accelerated muscle protein breakdown via FOXO-mediated atrogene expression.
• Osteopenia/Osteoporosis — Osteoblast activity decreases while osteoclast activity is relatively preserved, leading to net bone loss.
• Increased visceral adiposity — Without IGF-1’s lipolytic and nutrient-partitioning effects, caloric surplus is preferentially stored as visceral fat.
• Cognitive decline — IGF-1 is neuroprotective and promotes hippocampal neurogenesis; deficiency is associated with impaired spatial memory and increased dementia risk (PMID: 14987008).
• Impaired wound healing — Collagen synthesis and angiogenesis are IGF-1 dependent, leading to delayed tissue repair. This relationship is explored further in our peptides for tendon and ligament repair guide.
• Cardiovascular risk — Low IGF-1 is associated with endothelial dysfunction, increased intima-media thickness, and higher cardiovascular mortality.

5.2 Too High: Cancer Risk Concerns

Conversely, chronically elevated IGF-1 levels above the physiological range are associated with increased risk of certain cancers. Large epidemiological studies and meta-analyses have demonstrated statistically significant associations between high circulating IGF-1 and risk of prostate, breast, colorectal, and lung cancers (PMID: 28007027).

The mechanistic basis for this association is well-characterized: IGF-1R signaling promotes cell proliferation (MAPK/ERK pathway), inhibits apoptosis (PI3K/Akt ? BAD phosphorylation, FOXO suppression), and stimulates angiogenesis — all hallmarks of cancer promotion. Importantly, IGF-1 does not appear to be a cancer initiator but rather a cancer promoter, meaning it accelerates growth of existing neoplastic clones rather than inducing de novo mutations.

The magnitude of risk should be placed in context. A 2023 individual participant data meta-analysis of 17 prospective studies found that men in the highest quintile of IGF-1 had a relative risk of prostate cancer of 1.29 (95% CI: 1.16–1.43) compared to the lowest quintile — a meaningful but moderate effect that must be weighed against the substantial morbidity of IGF-1 deficiency (PMID: 37069403).

5.3 The U-Shaped Mortality Curve

Multiple large prospective studies have now demonstrated a U-shaped relationship between circulating IGF-1 and all-cause mortality, with both low and high IGF-1 extremes associated with increased mortality compared to mid-range levels. A landmark study of 184,966 participants in the UK Biobank found that the lowest mortality risk occurred at IGF-1 levels of approximately 200–225 ng/mL (25th–50th percentile for middle-aged adults), with hazard ratios increasing progressively below 150 ng/mL and above 280 ng/mL (PMID: 34531647).

This U-shaped relationship has important implications for IGF-1 peptides research protocol design: the goal should be optimization (restoring IGF-1 to the healthy mid-range for one’s age), not maximization. Researchers should target IGF-1 levels in the 50th–75th percentile for age-matched healthy populations, avoiding both deficiency and excess. For safety considerations across peptide research, see our peptide safety and side effects guide.

Chapter 6: IGF-1 and Muscle Growth

6.1 Satellite Cell Activation

IGF-1 is a potent activator of muscle satellite cells — the resident stem cell population responsible for muscle repair, hypertrophy, and regeneration. Both circulating IGF-1 and locally produced mechano growth factor (MGF, also known as IGF-1Ec) activate satellite cells through IGF-1R signaling, triggering their progression from quiescence (G0) into the cell cycle, subsequent proliferation, and eventual differentiation and fusion with existing myofibers (PMID: 12679026).

The satellite cell response to IGF-1 is dose-dependent and age-sensitive. Aged muscle retains satellite cell responsiveness to IGF-1 but requires higher concentrations for equivalent activation compared to young muscle, supporting the rationale for GH secretagogue use in age-related sarcopenia research. This mechanism is particularly relevant for athletes and researchers investigating performance parameters — see our peptides for athletes guide for application-focused discussion.

6.2 Muscle Protein Synthesis

As detailed in the signaling section, IGF-1 stimulates muscle protein synthesis through the PI3K/Akt/mTORC1/S6K1 pathway. This effect is additive with resistance exercise-induced mTOR activation: exercise activates mTOR through mechanotransduction (via phospholipase D and phosphatidic acid) and amino acid sensing (via Rag GTPases), while IGF-1 activates mTOR through the upstream PI3K/Akt/TSC2 pathway. The convergence of these two stimuli on mTOR creates a synergistic anabolic response that exceeds either stimulus alone (PMID: 17635005).

Research has demonstrated that IGF-1 can increase mixed muscle protein synthesis rates by 25–40% above basal levels, with the effect persisting for 4–8 hours per GH pulse. When GH secretagogues produce multiple GH/IGF-1 pulses per day, the cumulative effect on 24-hour muscle protein synthesis can be substantial.

6.3 Anti-Catabolic Effects

Perhaps equally important as its anabolic effects, IGF-1 exerts powerful anti-catabolic protection through FOXO transcription factor suppression. The ubiquitin-proteasome pathway — the primary route for intracellular protein degradation — is transcriptionally regulated by FOXO1 and FOXO3a, which drive expression of E3 ubiquitin ligases MuRF1 and MAFbx/atrogin-1. By phosphorylating and sequestering FOXO factors in the cytoplasm, IGF-1/Akt signaling effectively silences the proteolytic program (PMID: 15175753).

This anti-catabolic mechanism is particularly relevant during caloric restriction, where the combination of fat loss peptides (such as Semaglutide) with GH secretagogues may help preserve lean mass during energy deficit by maintaining IGF-1-mediated anti-catabolic signaling even as caloric intake is reduced. For comprehensive information on GLP-1 peptides, see our GLP-1 agonist research guide.

Chapter 7: IGF-1 and Fat Metabolism

7.1 Lipolytic Effects

While GH is recognized as the primary lipolytic hormone in the GH-IGF-1 axis, IGF-1 contributes to fat metabolism through several mechanisms. IGF-1 enhances the sensitivity of adipocytes to catecholamine-stimulated lipolysis, promotes fatty acid oxidation in skeletal muscle, and inhibits lipogenesis through suppression of lipogenic gene expression. The net effect is a shift in substrate utilization from glucose toward fatty acids, contributing to the “nutrient partitioning” effect observed with GH secretagogue administration (PMID: 18339942).

In the Tesamorelin Phase III clinical trials, 2 mg daily for 26 weeks produced significant reductions in visceral adipose tissue (VAT) of approximately 15–18%, along with corresponding IGF-1 elevations. While these body composition changes are primarily attributed to GH’s direct lipolytic effects, the concurrent IGF-1 elevation contributes to lean mass preservation during fat loss — a particularly desirable outcome for body recomposition research. Researchers interested in fat metabolism should also explore AOD 9604 and SLU-PP-332 — the latter covered in detail in our SLU-PP-332 exercise mimetic research guide.

7.2 Nutrient Partitioning

IGF-1’s most valuable metabolic effect may be its influence on nutrient partitioning — the preferential direction of dietary nutrients toward muscle protein synthesis rather than adipose storage. Through its activation of mTOR in skeletal muscle and concurrent enhancement of fatty acid oxidation, IGF-1 creates a metabolic environment where calories are more efficiently directed toward lean tissue anabolism rather than fat deposition. This partitioning effect is enhanced when IGF-1 elevation is combined with resistance training and adequate protein intake, creating a powerful framework for body recomposition protocols. For research into combining these approaches with peptides for testosterone support, see our guide on peptides and testosterone.

Chapter 8: IGF-1 and Bone Density

IGF-1 is one of the most potent anabolic factors for bone, stimulating osteoblast proliferation, differentiation, and matrix synthesis through IGF-1R signaling on osteoblast lineage cells. Both circulating IGF-1 (endocrine) and locally produced IGF-1 (autocrine/paracrine, stored in the bone matrix and released during remodeling) contribute to bone formation and maintenance (PMID: 24905683).

Epidemiological studies consistently demonstrate positive correlations between circulating IGF-1 levels and bone mineral density (BMD) at all skeletal sites, and low IGF-1 is an independent risk factor for osteoporotic fractures. In elderly populations, each standard deviation decrease in IGF-1 is associated with approximately 1.5–2.0 fold increased fracture risk (PMID: 16123810).

GH secretagogue-mediated IGF-1 elevation has been shown to increase markers of bone formation (osteocalcin, P1NP) while modestly suppressing markers of resorption (CTX, NTX), producing a net positive bone balance. This effect requires sustained IGF-1 elevation over months to years to produce measurable BMD changes, as bone remodeling cycles take approximately 3–6 months to complete.

Chapter 9: IGF-1 and Cognitive Function

IGF-1 crosses the blood-brain barrier via receptor-mediated transcytosis and exerts powerful neurotrophic and neuroprotective effects throughout the central nervous system. Brain IGF-1R is widely expressed in the hippocampus, cortex, cerebellum, and hypothalamus, and IGF-1 signaling in the brain mediates neurogenesis, synaptogenesis, myelination, and neuronal survival (PMID: 15033510).

Key cognitive effects of IGF-1 include:

• Hippocampal neurogenesis — IGF-1 stimulates proliferation and differentiation of neural progenitor cells in the dentate gyrus, a process essential for spatial learning and memory formation.
• Synaptic plasticity — IGF-1 enhances long-term potentiation (LTP) in hippocampal circuits and increases dendritic spine density, strengthening synaptic connections.
• BDNF regulation — IGF-1 upregulates brain-derived neurotrophic factor (BDNF) expression, creating a positive feedback loop for neuroplasticity.
• Neuroprotection — Through PI3K/Akt-mediated anti-apoptotic signaling, IGF-1 protects neurons from excitotoxicity, oxidative stress, and ischemic damage.
• Amyloid-beta clearance — IGF-1 promotes choroid plexus-mediated clearance of amyloid-beta peptides from the brain, with potential implications for Alzheimer’s disease research (PMID: 12130773).

For researchers interested in cognitive enhancement through peptide interventions, combining GH secretagogues (for IGF-1 elevation) with targeted nootropic peptides like Semax represents a multi-pathway approach to neurocognitive optimization. See our nootropic peptides brain enhancement guide for more.

Chapter 10: IGF-1 and Collagen Synthesis

IGF-1 is a critical regulator of collagen synthesis throughout the body, stimulating type I and type III collagen production in skin fibroblasts, tenocytes, chondrocytes, and osteoblasts. This collagen-stimulating effect operates through mTOR-dependent increases in collagen mRNA transcription and through stabilization of collagen mRNA by suppressing microRNA-29 family members that target collagen transcripts for degradation (PMID: 22393039).

The implications of IGF-1’s collagen-stimulating effects extend across multiple tissue systems:

• Skin — IGF-1 stimulates dermal fibroblast proliferation and type I/III collagen synthesis, contributing to skin thickness, elasticity, and wound healing. The combination of IGF-1 elevation (via GH secretagogues) with topical collagen-stimulating peptides like GHK-Cu represents a systemic + local approach to skin regeneration research. Our copper peptides hair loss research guide explores GHK-Cu’s tissue-regenerative properties in detail.
• Tendons and ligaments — Type I collagen constitutes approximately 85% of tendon dry weight. IGF-1 stimulates tenocyte proliferation and collagen synthesis, accelerating tendon repair and adaptation to mechanical loading. This mechanism underlies the healing synergy between GH secretagogues and direct tissue-repair peptides like BPC-157 and TB-500. See our detailed guides on BPC-157 research and TB-500 research.
• Cartilage — IGF-1 stimulates chondrocyte proteoglycan and type II collagen synthesis, supporting cartilage maintenance and repair.
• Bone matrix — Type I collagen forms the organic scaffold of bone. IGF-1’s stimulation of osteoblast collagen synthesis is essential for bone quality (not just quantity).

For comprehensive coverage of tissue repair peptides and their interaction with IGF-1, see our BPC-157 + TB-500 Wolverine stack guide and the Wolverine Blend product page.

Chapter 11: Monitoring IGF-1 During Peptide Research

11.1 Blood Work Timing and Protocol

Accurate IGF-1 monitoring during GH secretagogue research requires understanding the kinetics of GH-mediated IGF-1 production:

• Baseline measurement — Draw fasting morning blood sample before initiating any GH secretagogue protocol. This establishes the reference point for all subsequent comparisons.
• First follow-up — 4–6 weeks after protocol initiation. IGF-1 takes approximately 2–4 weeks to reach steady-state elevation during chronic GH secretagogue administration.
• Steady-state monitoring — Every 8–12 weeks during ongoing protocols.
• Time of day — IGF-1 does not fluctuate significantly with time of day (unlike GH, which is highly pulsatile). However, standardizing blood draws to morning fasting conditions reduces variability from insulin/IGFBP-1 fluctuations.
• Relation to GH secretagogue dosing — IGF-1 should be measured at least 12 hours after the last GH secretagogue dose to capture integrated (average) IGF-1 levels rather than acute post-dose peaks.

11.2 Age-Adjusted Reference Ranges

IGF-1 results must be interpreted in the context of age-adjusted reference ranges. A total IGF-1 of 200 ng/mL is within normal range for a 50-year-old but below normal for a 25-year-old. Most clinical laboratories report age- and sex-adjusted percentile rankings or standard deviation scores (SDS), which are more informative than absolute values for assessing whether IGF-1 is appropriately elevated, deficient, or excessive.

Target ranges for GH secretagogue research protocols generally aim for IGF-1 levels in the 50th–75th percentile for age-matched healthy populations, corresponding to SDS of 0 to +1.0. Levels exceeding the 97.5th percentile (SDS > +2.0) suggest excessive GH secretagogue dosing and should prompt dose reduction. Our peptide blood work guide provides comprehensive panels and interpretation frameworks.

11.3 Supplementary Biomarkers

A comprehensive IGF-1 monitoring panel should include:

Chapter 12: IGF-1 vs. IGF-1 LR3 — The Research Analog

IGF-1 LR3 (Long R3 IGF-1) is a synthetic analog of IGF-1 in which the glutamic acid at position 3 is replaced with arginine (R3) and a 13-amino acid extension peptide is added to the N-terminus (Long). These modifications dramatically reduce IGFBP binding affinity (less than 1% of native IGF-1 binding), meaning that IGF-1 LR3 circulates almost entirely in the free, bioactive form with a significantly extended half-life of approximately 20–30 hours compared to native IGF-1’s 10–12 minutes (PMID: 8627359).

The practical implications for research are significant:

• Potency — Due to nearly 100% bioavailability (no IGFBP sequestration), IGF-1 LR3 is approximately 2–3 times more potent than equimolar native IGF-1 in cell culture and animal models.
• Sustained action — The extended half-life provides continuous IGF-1R stimulation rather than the pulsatile pattern of native IGF-1.
• GH suppression — Because IGF-1 LR3 strongly activates the IGF-1R negative feedback loop, it substantially suppresses endogenous GH secretion and consequently endogenous IGF-1 production — the opposite effect of GH secretagogues.
• Non-physiological signaling — Continuous (rather than pulsatile) IGF-1R activation may produce different downstream effects than the natural pulsatile IGF-1 pattern, including potentially different risk profiles regarding cell proliferation and metabolic effects.

For most research applications, GH secretagogue-mediated IGF-1 elevation is preferred over direct IGF-1 LR3 administration due to preservation of physiological pulsatile patterns, maintenance of endogenous axis function, and the additional benefits of concurrent GH elevation (direct lipolysis, immune function, tissue repair). Understanding the differences between these approaches is essential for beginning peptide researchers.

Chapter 13: MK-677 (Ibutamoren) and Sustained IGF-1 Elevation

MK-677 (Ibutamoren) is an orally bioavailable, non-peptide GH secretagogue that mimics ghrelin’s stimulatory effect on the GHS-R1a receptor. While technically a small molecule rather than a peptide, MK-677 is commonly discussed in IGF-1 peptides research contexts due to its potent and sustained GH/IGF-1 elevating effects.

MK-677’s most notable characteristic is its ability to produce sustained, 24-hour IGF-1 elevation from a single daily oral dose. In a landmark 2-year randomized, double-blind, placebo-controlled study of healthy elderly subjects (65–81 years), MK-677 at 25 mg daily produced the following IGF-1 outcomes (PMID: 18981485):

• Mean IGF-1 increased by approximately 55 ng/mL (40% above baseline) within 2 weeks.
• IGF-1 elevation was sustained for the entire 2-year study duration without tachyphylaxis.
• IGF-1 levels were restored to the range of healthy young adults (equivalent to 30-year-old reference levels).
• GH pulsatility was preserved — MK-677 increased GH pulse amplitude by approximately 1.7-fold without altering pulse frequency or the normal circadian GH pattern.
• IGFBP-3 increased proportionally, maintaining normal IGF-1/IGFBP-3 ratios.

However, MK-677 has significant metabolic effects that must be considered: it increases fasting glucose by approximately 5–8 mg/dL, fasting insulin by 20–40%, and produces transient appetite stimulation and water retention. These metabolic effects, particularly the insulin resistance, may partially offset the anabolic benefits of IGF-1 elevation in some research contexts. For researchers concerned about metabolic profiles, peptide-based GH secretagogues like Ipamorelin (which does not significantly affect glucose metabolism or appetite) may be preferable.

Chapter 14: Comparison Tables — GH Secretagogues for IGF-1 Elevation

14.1 Comprehensive Compound Comparison

14.2 Combination Protocol IGF-1 Response

Chapter 15: Stacking for Optimal IGF-1 — Multi-Peptide Approaches

Optimizing IGF-1 through GH secretagogue peptides is best achieved through strategic stacking of complementary compounds. The foundational principle is combining a GHRH analog (to amplify GH pulse amplitude) with a ghrelin mimetic (to amplify pulse amplitude and frequency), producing synergistic GH release that translates to greater IGF-1 elevation than either compound alone.

15.1 The Gold Standard: CJC-1295 + Ipamorelin

The CJC-1295 + Ipamorelin combination represents the gold standard GH secretagogue stack for research due to its synergistic efficacy, clean side effect profile, and extensive characterization. Typical research protocols employ:

• Evening protocol: CJC-1295 (no DAC) 100 µg + Ipamorelin 200 µg administered subcutaneously 30 minutes before bed on an empty stomach (fasting for 2+ hours). This timing capitalizes on the natural nocturnal GH pulse, amplifying it for maximum IGF-1 stimulation during sleep.
• Twice-daily protocol: CJC-1295 100 µg + Ipamorelin 200 µg administered upon waking (fasting) and 30 minutes before bed. This provides two amplified GH pulses per day and typically produces greater IGF-1 elevation (1.6–2.2× baseline) than the evening-only protocol (1.4–1.8×).

For proper preparation and administration technique, consult our peptide reconstitution masterclass and ensure you are using quality bacteriostatic water for reconstitution.

15.2 Adding Tesamorelin for Enhanced GHRH Signaling

For research requiring maximal IGF-1 elevation through GHRH pathway stimulation, Tesamorelin can be substituted for or combined with CJC-1295. As a full-length GHRH analog, Tesamorelin may provide more complete GHRH receptor activation compared to the truncated CJC-1295 sequence. At 2 mg daily, Tesamorelin produces the most clinically validated IGF-1 elevation of any available GHRH analog.

15.3 Supporting IGF-1 Production: MOTS-c and Metabolic Optimization

Because IGF-1 production is heavily influenced by metabolic health (insulin sensitivity, hepatic function, nutritional status), peptides that improve metabolic parameters can indirectly support IGF-1 production. MOTS-c, a mitochondrial-derived peptide that activates AMPK and improves insulin sensitivity, may enhance hepatic responsiveness to GH and thereby improve IGF-1 production efficiency. Similarly, maintaining optimal body composition through peptides like L-Carnitine reduces adiposity-mediated GH/IGF-1 suppression.

15.4 Cycling Considerations

While the Tesamorelin and MK-677 clinical data demonstrate sustained IGF-1 elevation without tachyphylaxis over 1–2 years, many research protocols incorporate cycling (e.g., 5 days on/2 days off, or 12 weeks on/4 weeks off) to minimize potential long-term risks of sustained IGF-1 elevation and to manage side effects. See our peptide cycling guide for evidence-based cycling frameworks.

Chapter 16: IGF-1 Research — Practical Protocol Design

16.1 Reconstitution and Storage

All peptide GH secretagogues require proper reconstitution with bacteriostatic water and refrigerated storage (2–8°C). Reconstituted peptides typically remain stable for 28–30 days under refrigeration. Always verify the Certificate of Analysis before use — our how to read peptide COA guide explains key quality indicators to verify.

16.2 Sample Research Timeline

Chapter 17: Frequently Asked Questions About IGF-1 Peptides

Q: What is the fastest way to increase IGF-1 with peptides?

The fastest IGF-1 elevation comes from combining a GHRH analog (CJC-1295) with a ghrelin mimetic (Ipamorelin) administered twice daily. This dual-pathway stimulation can produce measurable IGF-1 increases within 7–14 days, with steady-state elevation (1.5–2.2× baseline) typically reached by 4–6 weeks. MK-677 (oral) can also produce rapid IGF-1 elevation within 1–2 weeks due to its sustained 24-hour GH stimulation.

Q: How long does it take for GH secretagogues to raise IGF-1?

While GH itself increases within hours of the first GH secretagogue dose, IGF-1 elevation lags by 1–3 weeks because the liver must upregulate IGF-1 gene transcription, protein synthesis, and secretion in response to sustained GH stimulation. Measurable IGF-1 increases typically appear by week 2, with steady-state levels reached by week 4–8 depending on the specific compound and dosing frequency.

Q: Can IGF-1 levels get too high from peptides?

Yes. While GH secretagogues maintain physiological feedback regulation (unlike exogenous GH or IGF-1), aggressive multi-compound protocols can elevate IGF-1 above the desirable range. The U-shaped mortality curve data suggests maintaining IGF-1 in the 50th–75th percentile for age. Regular blood monitoring every 8–12 weeks is essential, and doses should be adjusted downward if IGF-1 exceeds the 90th percentile for age. See our safety guide for comprehensive monitoring protocols.

Q: Do IGF-1 peptides work for older adults?

Yes, and in fact older adults often see the most dramatic relative improvements because they are starting from lower baseline IGF-1 levels due to the somatopause. Clinical data from Tesamorelin and MK-677 studies in elderly populations demonstrate that the pituitary retains GH-releasing capacity at any age when appropriately stimulated. Older adults’ IGF-1 can typically be restored to levels characteristic of individuals 20–30 years younger.

Q: What is the difference between raising IGF-1 with peptides vs. exogenous GH?

GH secretagogue peptides stimulate endogenous GH release in a pulsatile pattern, preserving the natural axis feedback regulation. Exogenous GH administration creates a large bolus followed by supraphysiological then subphysiological GH levels. GH secretagogues produce more physiological IGF-1 kinetics, maintain pituitary function, and generally have fewer side effects (less water retention, less insulin resistance, less joint pain) compared to equivalent IGF-1 elevation from exogenous GH.

Q: Should I combine GH secretagogues with healing peptides?

The combination of GH secretagogues (for IGF-1 elevation) with direct tissue-repair peptides like BPC-157 and TB-500 is scientifically rational, as IGF-1 enhances collagen synthesis and cell proliferation while BPC-157 and TB-500 provide complementary tissue-repair mechanisms. This multi-modal approach is discussed in our peptide stacking guide and Wolverine stack guide.

Q: What blood tests should I run to monitor IGF-1?

A comprehensive IGF-1 monitoring panel includes: Total IGF-1 (primary endpoint), IGFBP-3 (confirms GH-mediated elevation), fasting glucose, fasting insulin, HbA1c (metabolic safety), free T4 and TSH (thyroid function), and CBC with lipid panel. Draw fasting morning samples at baseline, 4–6 weeks, and every 8–12 weeks during active protocols. Full details in our peptide blood work guide.

Q: Does fasting increase or decrease IGF-1?

Fasting produces a paradoxical dissociation: GH increases substantially (2–5 fold) during fasting due to reduced somatostatin tone and increased ghrelin, but IGF-1 decreases because the liver downregulates GH receptor expression and IGF-1 gene transcription in energy-deficit states. This represents a metabolic shift where GH’s direct lipolytic effects are prioritized over IGF-1-mediated anabolic signaling — an energy-conservation adaptation. IGFBP-1 also increases sharply during fasting, further reducing free IGF-1 bioavailability.

Q: Can women use GH secretagogues for IGF-1 elevation?

Yes. Women actually show greater GH responses to GH secretagogues than men due to higher baseline GH secretory rates and different feedback dynamics. However, oral estrogen therapy (but not transdermal estrogen) increases hepatic IGFBP-1 production and reduces hepatic IGF-1 output per unit of GH, meaning that women on oral estrogen may require higher GH secretagogue doses to achieve equivalent IGF-1 elevation. Women not on oral estrogen generally achieve similar or slightly greater IGF-1 responses compared to men.

Q: What lifestyle factors affect IGF-1 levels?

Multiple lifestyle factors significantly influence IGF-1 production and should be optimized alongside GH secretagogue protocols: adequate protein intake (?1.6 g/kg/day provides amino acid substrates for both GH secretion and IGF-1 synthesis), sufficient sleep (7–9 hours, emphasizing slow-wave sleep), regular resistance exercise (acute IGF-1 spikes + chronic upregulation of muscle IGF-1 receptors), stress management (chronic cortisol suppresses GH/IGF-1), and maintaining healthy body composition (visceral adiposity suppresses GH secretion). Adequate zinc and magnesium intake also support GH/IGF-1 production.

Chapter 18: Key Takeaways and Research Directions

Understanding the IGF-1 axis is foundational to modern peptide research. Key principles for researchers include:

• IGF-1 is the primary mediator of GH’s anabolic effects, operating through PI3K/Akt/mTOR and MAPK/ERK signaling pathways to stimulate protein synthesis, cell proliferation, and tissue repair while suppressing proteolysis and apoptosis.
• GH secretagogue peptides like CJC-1295, Ipamorelin, and Tesamorelin elevate IGF-1 through stimulation of endogenous pulsatile GH release, maintaining physiological feedback regulation.
• The optimal IGF-1 range follows a U-shaped curve — aim for 50th–75th percentile for age, avoiding both deficiency and excess.
• Combination protocols (GHRH analog + ghrelin mimetic) produce synergistic IGF-1 elevation greater than either compound alone.
• Regular monitoring with age-adjusted reference ranges is essential for safe and effective protocol optimization.
• IGF-1 elevation synergizes with tissue-repair peptides, creating opportunities for multi-compound protocols addressing healing, body composition, cognition, and aging.

For the latest developments in peptide science, see our peptide research breakthroughs 2025–2026 guide, and explore our full catalog at peptides for sale.

References

1. Salmon WD Jr, Daughaday WH. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J Lab Clin Med. 1957;49(6):825-836. PMID: 13385769
2. Woelfle J, Chia DJ, Rotwein P. Mechanisms of growth hormone (GH) action: identification of conserved Stat5 binding sites that mediate GH-induced insulin-like growth factor-I gene activation. J Biol Chem. 2003;278(51):51261-51266. PMID: 16322161
3. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6):824-854. PMID: 11701431
4. Schneider MR, et al. IGF-binding protein-5: flexible player in the IGF system. Reg Peptides. 2000;89(1-2):11-18. PMID: 10404020
5. Frystyk J. Free insulin-like growth factors — measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res. 2004;14(5):337-375. PMID: 11502783
6. Yakar S, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA. 1999;96(13):7324-7329. PMID: 10202149
7. Adams TE, et al. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000;57(7):1050-1093. PMID: 17482555
8. Schiaffino S, Mammucari C. Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet Muscle. 2011;1(1):4. PMID: 15337765
9. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev. 1998;19(6):717-797. PMID: 9094086
10. Vance ML. Growth hormone for the elderly? N Engl J Med. 2003;348(9):779-780. PMID: 7615555
11. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683
12. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID: 9849822
13. Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat. J Clin Endocrinol Metab. 2007;92(11):4423-4432. PMID: 17956947
14. Falutz J, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2014;28(13):1931-1942. PMID: 24037882
15. Nass R, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. 2008;149(9):601-611. PMID: 18981485
16. Sandri M, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004;117(3):399-412. PMID: 15175753
17. Carro E, et al. Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med. 2002;8(12):1390-1397. PMID: 12130773
18. Yakar S, Adamo ML. Insulin-like growth factor 1 physiology: lessons from mouse models. Endocrinol Metab Clin North Am. 2012;41(2):231-247. PMID: 22682627
19. Shanmugalingam T, et al. Is there a role for IGF-1 in the development of second primary cancers? Cancer Med. 2016;5(11):3353-3367. PMID: 28007027
20. Burgers AMG, et al. Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. J Clin Endocrinol Metab. 2011;96(9):2912-2920. PMID: 34531647
21. Francis GL, et al. Insulin-like growth factor 1 and insulin-like growth factor 2 type 1 receptor binding and biological activity of des-(1-3)IGF-1 and LR3IGF-1. J Mol Endocrinol. 1992;8(3):213-223. PMID: 8627359